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Structured exercise improves calf muscle pump
function in chronic venous insufficiency: A
randomized trial
Frank T. Padberg, Jr, MD,a,b Mark V. Johnston, PhD,a,c and Sue Ann Sisto, PT, MA, PhD,a,c Newark,
East Orange, and West Orange, NJ
Objective: Deterioration of calf muscle pump function is associated with progression of chronic venous insufficiency
(CVI). We postulated that a supervised exercise program would improve calf muscle strength and venous hemodynamics
in patients with CVI.
Methods: We recruited 31 patients for this randomized, prospective trial. Inclusion criteria required the presence of skin
changes or ulceration (CEAP 4, 5, 6), and duplex ultrasound scanning (reflux or scarring) and air plethysmographic
(APG) evidence of CVI. Subjects were randomized into control (n  13) and therapy (n  18) groups. Class II (30-40
mm Hg) compression hosiery was given to all. The experimental group received physical therapy designed specifically to
strengthen calf musculature. Dynamic strength and power were measured with a Biodex II dynamometer (Biodex Medical
Systems, Shirley, NY) at slow and fast speeds. Reflux (venous filling index) and calf pump function (ejection fraction,
residual volume fraction) were measured with APG. Quality-of-life questionnaires and venous severity scores were also
administered. Outcomes were compared 6 months after initiation of exercise. Probability of treatment effect was tested
with univariate analysis of variance, with control for baseline values.
Results: Demographic variables and medical comorbidities were not different between groups. After 6 months of
intervention, indicators of calf pump function returned to a normal range in the therapy (experimental) group. Mean
residual volume fraction was improved in the exercise group (8.75  4.6 vs 3.4  2.9 in the control group; P < .029).
Mean ejection fraction was increased in the exercise group (3.48  2.7 vs 1.4  2.1 in the control group; P < .026).
Reflux, while substantially greater than the normal value of 2.0 mL/s in both groups, was unchanged. The exercise
regimen improved isokinetic peak torque/body weight at both slow speed (3.1 1.4 in the therapy group vs1.0 1.1
in the control group; P < .05) and fast speed (2.8  0.9 in the therapy group vs  0.3  0.6 in the control group; P <
.03). No changes were observed in quality-of-life or severity scores.
Conclusions: Calf muscle pump function and dynamic calf muscle strength were improved after a 6-month program of
structured exercise. Directed physical conditioning of the calf musculature may prove beneficial for patients with or
without alternative management options for severe CVI. Further research on exercise for patients with CVI is warranted.
(J Vasc Surg 2004;39:79-87.)
Treatment options are limited for patients with severe
chronic venous insufficiency (CVI). Limbs with advanced
CVI are often perfunctorily categorized as postthrombotic,
and as a result are infrequently assessed for location and
cause of disease. When recognized and indicated, substan-
tial improvement is reported after surgical intervention.1,2
However, many patients remain chronically debilitated as a
result of CVI symptoms. A mainstay of therapy, an appro-
priately prescribed compression garment, continues to pro-
vide substantial relief for patients with severe CVI, regard-
less of cause. If physiologic function can be improved with
exercise, this too may provide additional therapeutic bene-
fit.
Although commonly advocated in Europe, physical
therapy for CVI has not been widely adopted in North
America. Reduced ankle range of motion (ROM) and
diminished calf muscle pump function are associated with
progressive severity of CVI.3-6 We reasoned that physical
conditioning structured to enhance calf muscle strength
and ankle mobility would improve venous hemodynamics
by improving calf muscle pump function. In turn, gains in
musculoskeletal function and venous hemodynamics
should translate into improved functional mobility and
general well-being.
METHODS
Subjects with advanced CVI were recruited for this trial
from an outpatient veterans clinic population. Demo-
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graphic information and comorbidities were recorded;
CEAP classifications and severity scores were assigned.
Functional and quality-of-life (QOL) instruments were
administered. Investigations included comprehensive ve-
nous duplex ultrasound scanning, air plethysmography
(APG), and isokinetic dynamometry (Biodex Medical Sys-
tems, Shirley, NY).7-10
Initial evaluation included a history and clinical exam-
ination, with attention to related comorbidities, including
obesity, diabetes, cardiorespiratory dysfunction, musculo-
skeletal impairment, and prior thrombosis. Obesity was
defined as body mass index greater than 30, calculated as
weight in kilograms divided by height in meters squared.
Arterial insufficiency was defined as ankle-brachial index
(ABI) less than 0.7.
Inclusion criteria required the presence of skin changes
or ulceration (CEAP clinical classes 4, 5, 6), as well as
objective evidence of CVI as determined with duplex ultra-
sound scanning and APG. Exclusion criteria included ul-
ceration greater than 4 cm in diameter, painful ulceration,
active local infection, recognized noncompliance, absence
of objective evidence of a venous cause, uncompensated
cardiorespiratory insufficiency, ABI less than 0.7, and re-
cent venous thrombosis. In general, limbs with active ul-
ceration or infection were stabilized, with a decrease in
ulcer diameter to less than 2 cm and control of pain or local
infection before screening; volunteers did not proceed to
consideration until they could wear the study stocking
regularly (no alternative bandages were used once recruit-
ment and testing had begun). In lieu of therapy, superficial
vein surgery was offered to those with appropriate anatomy.
The experimental intervention was carried out in the vas-
cular laboratory or clinic, and the physical therapy depart-
ment, but, when necessary, supervision of therapy was
extended into satellite clinics or the patient’s home.
Duplex ultrasound scanning was conducted with a
Sonoline Elegra or Quantum 2000 (Siemens, Iselin, NJ)
scanner, with 2.5 to 7.5 mHz probes. An imaging survey
evaluated standard sites in both lower extremities for pa-
tency, compressibility, wall thickness, scarring, and throm-
bosis of any duration. Limbs were evaluated with the pa-
tient in the standing position, and reflux was noted when
retrograde flow persisted longer than 0.5 seconds after
distal compression and release.11,12 Venous anatomic
scores for reflux and obstruction, both of which range from
0 to 10, were computed from these data.8
Severity of CVI was characterized with both the Ve-
nous Clinical Severity Scores (VCSS) and the older Venous
Clinical Scores.8,9 The VCSS has 10 items, with severity
rated 0 to 3 by the examiner; it is reported as a numeric
score, which ranges from 0 to 30. Increasing linearly with
the clinical classification, a mean score of 14.9  2.88 was
reported for limbs with C6 CVI.13 The venous clinical
score has 9 items, with a range of 0 to 18.9 The Venous
Disability score was also recorded.
Hemodynamic and musculoskeletal variables were de-
termined with APG and ankle isokinetic dynamometry
(Biodex). Because extremes of human performance are
demanded with these functional measures, there is a greater
likelihood of variability from test to test; thus examinations
were completed twice, and the baseline value was reported
as the mean of the two baseline hemodynamic and isoki-
netic tests.
Air plethysmography. APG (APG-1000, ACI Medi-
cal, San Marcos, Calif) provides a noninvasive, easily repeat-
able, reliable method for determination of reflux volume,
outflow, and calf pump function. Reflux measured with
APG is expressed as venous filling index (VFI; venous
volume in milliliters per second of refill time). Increasing
values of VFI have been associated with progressive clinical
symptoms of chronic venous insufficiency, including ulcer-
ation.6 An outflow fraction less than 38% is associated with
venous outflow obstruction; outflow fraction less than 28%
is considered poor outflow. Calf pump function is reflected
by volume changes with muscular activity; calf volumes are
indexed to the total venous volume to obtain the ejection
fraction (EF) and residual volume fraction (RVF). EF is the
volume ejected with a single toe raise maneuver, and RVF is
the volume remaining after 10 toe raises. A linear correla-
tion between ambulatory venous pressure and RVF (r 
0.83) has been described.14 Deficiencies in calf pump func-
tion have also been associated with increased occurrence of
ulcers.3,4,14 In addition, progressive severity of CVI was
associated with decreased ankle ROM.4 Examinations were
performed without stockings in the morning hours on two
separate days, and conducted as described by Araki et al,3
Back et al,4 and Christopoulous et al.6 Testing included EF,
RVF, VFI, and outflow fraction.
Ankle isokinetic dynamometer. A Biodex System 2
multi-joint testing and rehabilitation system (Biodex) with
Biodex Advantage Software (version 4.0; Biodex) was used
for collecting data on calf torque, work, power, and ROM.
Subjects were tested for ankle plantar flexion and extension
twice, 1 week apart. The anatomic ankle joint was posi-
tioned at the rotational axis of the machine, and contrac-
tions started from full dorsiflexion, with the concentric
mode for slow (60 degrees per second) and fast (120
degrees per second) plantar flexion speeds. Each participant
completed five repetitions for the slow speed, followed by
15 repetitions for the fast speed. Compensatory motion was
prevented by a three-point seatbelt to prevent trunk and
pelvic musculature from contributing to ankle plantar flex-
ion; thus ankle isokinetic measurements were maximally
isolated. Tests were conducted as described by Sisto et al10
and Holback et al.15
The parameters evaluated were the average of all con-
tractions for peak torque, peak torque per unit body
weight, maximal repetition work, total work, average
power, and maximal ROM. Peak torque represents the
highest amount of tension a muscle can develop at one
instant in the ROM at specific test speeds. Peak torque per
unit body weight represents the peak torque normalized for
an individual’s body weight, to allow for comparisons
across subjects. Maximal repetitions work represents the
maximal amount of work exerted over the number of
repetitions in the set. Total work is the area under the peak
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torque curve. Total work may be better representative of
functional ability of a joint, because it is a measure of the
amount of torque that can be maintained throughout the
ROM. Power is the product of force and velocity. Average
power is work of one or several contractions over a specified
time. Average power may be considered a true measure of
work intensity. Reliability of the Biodex values is reported
elsewhere, and all measured variables exceeded an intraclass
correlation coefficient of 0.7.10
Functional and QOL assessment. Participants also
completed a series of questionnaires assessing QOL and
functional capacity at 0 and 6 months. Two QOL instru-
ments specifically target venous insufficiency: the Aberdeen
Varicose Vein Survey2 and the CIVIQ.16 The physical
function items (PF10) of the SF-36 were also employed.2
The Functional Independence Measure, Craig Handicap
and Reporting Techniques, and older American resources
and services questionnaire were administered to test for
function in daily life as opposed to ability.17 A separate,
nonvalidated questionnaire was also administered to in-
quire about specific issues relevant to this particular study.
These were analyzed by standard scoring techniques.
Randomization. Appropriately selected patients were
randomized into two unblinded groups: a control group
and a therapy (experimental) group. Patients in the control
group were fully evaluated at baseline (0 months) and again
at 6 months; monthly monitoring was scheduled to con-
firm and reinforce appropriate use of compression stock-
ings. After completion of their 6-month evaluation, volun-
teers in the control group were offered the opportunity to
participate in supervised therapy as wait-listed participants.
The data for the wait-listed control subjects is not reported
in this article. If CVI was present bilaterally, the more
affected limb was selected as the study limb, assuming that
it would have the greatest effect on function. All partici-
pants received two pairs of class II (30-40 mm Hg), below-
knee, compression hosiery and instruction in their use, thus
standardizing optimal medical treatment for both groups.
Exercise prescription. Subjects randomized to the
experimental group received 3 months of supervised ther-
apy followed by 3 months of unsupervised therapy. The
program was designed by a physical therapist (S.A.S.) and
individualized for each participant, with both written and
graphic instructions. The exercises chosen were standard
clinical practice and conducted by a physical therapy assis-
tant. Clinical examinations, APG, and isokinetic dynamom-
etry were performed at baseline, 3 months, and 6 months.
While most subjects came to our clinic for all of these
sessions, some were constrained by travel difficulties; when
necessary, the supervised therapy was continued by the
physical therapy assistant at the subject’s home or a local
satellite clinic. The physical training program was designed
to strengthen calf musculature and enhance joint mobility.
The exercise program consisted of lower limb and trunk
stretching and strengthening, with active gravity strength-
ening and resistive weights in two sessions per week. Phys-
ical training focused on leg strengthening, primarily of the
calf musculature, and progressed in repetitions, sets, and
weights throughout the 3 months. Uphill treadmill walk-
ing was included in each session of the supervised compo-
nent of the intervention, to further strengthen the calf, and
participants were encouraged to walk uphill while main-
taining their exercise program during the unsupervised
component. Each session consisted of approximately 1
hour of individualized therapy. Patients were taught the
principles of exercise progression, and were asked to con-
tinue the progression for an additional 3 months unsuper-
vised. Participants submitted exercise training logs that
were completed for each session in both supervised and
unsupervised components of the study. Compliance was
documented as the number of days attending supervised
exercise, and the number of days exercises were completed
or not, for example, because of illness or vacation, in the
unsupervised phase.
We hypothesized that physical conditioning structured
to enhance calf muscle strength and ankle mobility would
improve venous hemodynamics by improving calf muscle
pump function. In turn, gains in musculoskeletal function
and venous hemodynamics should translate into improved
functional mobility and general well-being. The primary
outcome variables were APG measures of calf pump func-
tion, that is, EF and RVF; in addition, we assessed the
following hemodynamic variables: venous filling index,
outflow fraction, EV, and venous volume. Secondary out-
come variables included the various measures of strength,
endurance, and ROM from isokinetic dynamometry, and
various functional and QOL instruments.
Randomization and statistics. Group assignment
was based on a previously prepared confidential random-
ized list. Candidates completing the initial evaluation and
consent were given a case number, and the study statistician
(M.V.J.) reported the group assignment.
Differences in means of outcome variables between
therapy and control groups were initially tested with simple
uncontrolled t tests. Distribution shape and outliers were
examined. Nonparametric analyses (Mann-Whitney U test,
Kolmogorov-Smirnov test) are not presented, because dis-
tribution shapes were not radically non-normal, and results
of these analyses did not differ appreciably. Mean baseline
values were computed from the two performance measures
(APG; Biodex). Then, controlling for a linear association
with the baseline value, treatment effects were estimated
with univariate analysis of variance (ANOVA) with SPSS
version 10.0.5 (SPSS, Chicago, Ill). Statistical significance
was accepted in this exploratory study at the conventional
level (P  .05).
The institutional review board approved the protocol;
each subject participated with informed consent. Funding
was awarded through the Merit Review Board, Department
of Veterans Affairs, Veterans Health Administration, Reha-
bilitation Research and Development.
RESULTS
We screened 77 patients for this prospective trial
funded by the Department of Veterans Affairs between
September 1999 and November 2002. All had skin changes
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or ulceration (CEAP clinical classes 4, 5, 6), as well as
objective evidence of CVI as determined with duplex ultra-
sound scanning (reflux or scarring) and APG. Potential
candidates (n  46) were excluded for often overlapping
reasons; these included refusal (n  10), inability to com-
plete the exercise or testing (n  6), painful ulcer (n  1),
failure to meet inclusion criteria (n  12), nonvenous
findings (n  10), acute thrombosis (n  1), arterial
insufficiency (n  3), and election of surgical intervention
(n  9). Failure to meet criteria included known noncom-
pliant patients; nonvenous findings included 7 candidates
with class III obesity, with minimal anatomic evidence of
venous disease.18 Details of patient accession and flow are
summarized in Table I, as recommended by the most
recent Consolidated Standards of Reporting Trials docu-
ment.19 Although initially randomized to therapy, one
individual failed to receive the intervention; recurrence of
painful ulceration occurred before collection of any out-
come measures, which precluded participation in the exer-
cise and testing methods, and the patient was excluded
from further analyses.
Thus 30 subjects with bona fide venous insufficiency
were enrolled, randomized, and analyzed in control (n 
13) and experimental (n  17) groups (Table I, online
only). In the control intervention, that is, stockings alone,
no patients were lost to follow-up and all completed the
6-month analysis. In the experimental intervention, that is,
therapy and stockings, follow-up was incomplete for 2
subjects. One completed 4 months of therapy before dis-
continuing because of unrelated psychiatric reasons; the
other completed 5 months, but failed to attend for the sixth
and final assessment. Beyond the painful ulceration and the
unrelated psychiatric problem, no adverse events tran-
spired.
Age, height, weight, and ABI were typical for a popu-
lation of subjects with advanced venous insufficiency (Table
II). Comorbid medical conditions were frequent in this
group with a mean age of 70 years, and included obesity,
coronary heart disease, angina, hypertension, dyspnea,
asthma, and diabetes. Cardiac failure was present in 10% of
our subjects, but none had renal or hepatic failure. Al-
though arthritis and other musculoskeletal conditions may
secondarily affect venous function, their incidence was dis-
tributed equally in both groups. A medical history of pre-
vious venous thrombosis was recorded in 50% of patients;
however, duplex ultrasound scans demonstrated an abnor-
mal deep venous lumen in only 30%. In either case, no
difference was detected between the two groups (Tables II,
III).
All volunteers had advanced CVI, with a distribution of
60% in CEAP class 4, and 40% with ulceration from CEAP
classes 5 and 6 (Fig, online only). Cause was secondary in
47%, but objective evidence of a partially obstructive patho-
physiologic condition was confirmed in only 27%. Statisti-
cal assessment identified no differences between the two
groups (Table IV). The anatomic components of venous
insufficiency are delineated in Table III; deep venous insuf-
ficiency predominates, as would be expected. Mean venous
severity scores (Table IV) are consistent with the advanced
CVI required by the eligibility criteria. Anatomic scores for
reflux and obstruction are given in Table IV. None of the
initial differences between experimental and control groups
were statistically significant (Tables I-IV).
Baseline (month 0) calf pump functions (mean EF,
RVF) were abnormal; mean baseline reflux (VFI) was also
abnormal (Table V). Mean RVF in the experimental inter-
vention group returned to normal after 6 months of ther-
apy. Univariate ANOVA, controlling for baseline values,
Table I. Flow of candidates through screening, recruitment, and participation
Patients No. Control group
Experimental
(therapy) group Commentary
Assessed for enrollment 77 Recruited and screened for eligibility
Excluded 46 Excluded for failure to meet criteria,
refusal, inability to complete studies,
other medical contraindications,
nonvenous ulceration, surgical preference
Subjects
Randomized dropouts
31
1
13
0
18
1
Refused to complete initial assessment, any
intervention, or data collection;
postrandomization complaint of pain
Trial subjects 30 13 17 Received allocated intervention
Lost to follow-up 1 0 1 Psychiatric decompensation; 4 mo
Discontinued intervention 1 0 1 Failed to return for 6-mo exams
Analyzed subjects 28 13 15 One incomplete
Excluded 0 0 0 None totally, but some cases were deleted
from some analyses because of missing
data for a key item or because recorded
value was impossible or an extreme
outlier (eg, 5 SD from mean of other
values)
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tested for differences in outcomes, and detected an effect of
therapy on EF and RVF (Table V); that is, in comparing the
experimental group with the control group, EF increased
significantly (P .026) and RVF decreased significantly (P
 .029). While the magnitude of VFI (reflux) was consis-
tent with severe CVI, no effects on VFI were observed or
expected. No differences were observed between the two
groups at baseline. Although a 6-month difference was
observed between groups for outflow fraction (obstruc-
tion), mean outflow fraction values were not in the range
considered abnormal. Thus, while a difference in outflow
fraction was observed, it is unlikely to be of clinical signifi-
cance. Similarly, no changes in VCSS were observed after 6
months.
Mean peak torque per unit body weight improved in
the exercise group, but not in the control group (Table VI).
Univariate ANOVA, controlling for baseline values, de-
tected a difference for both the slow (P .053) and fast (P
 .033) test conditions. Slow and fast peak torque im-
proved in comparison with control values in those receiving
the exercise regimen. None of the other Biodex measure-
ments demonstrated a difference between groups at 6
months. The exercise group tended to improve, at least
slightly, in all other Biodex parameters, while the control
group did not; trends for these other parameters, however,
did not reach statistical significance.
No differences between groups were observed in the
multiple QOL, functional, or perceived impairment instru-
ments used in this protocol; thus data on these secondary
outcomes are not presented. Compliance with both super-
vised and unsupervised exercise was good. During the
supervised phase, subjects participated in a mean 18  1.6
of 22 scheduled sessions. During the unsupervised phase,
participants reported exercising on a mean of 63 7.3 of a
possible 90 days. Stocking compliance was excellent, with
89% of patients wearing the stockings for a mean of 6.24
days and 95 hr/wk at the outset; 97% compliance was
achieved at month 6, with similar hours per week and days
of use.
DISCUSSION
The benefits of physical conditioning for patients with
arterial occlusive disease (claudication), coronary disease,
and musculoskeletal dysfunction have long been recog-
nized.20 However, to our knowledge, the efficacy of phys-
ical conditioning has never been convincingly demon-
strated in patients with CVI. Calf muscle, like dermis, may
Table III. Duplex ultrasound: distribution of findings
Control
group
Therapy
group
Both
groups
n % n % n %
Superficial 1 6 1 3
Deep 2 12 2 7
Perforator
Superficial  deep 4 31 4 24 8 27
Superficial  perforator 2 12 2 7
Deep  perforator
Super  deep  perforator 9 54 8 47 17 50
Evidence of chronic
thrombosis (scarring,
wall thickening,
incompressibility)
5 38 4 24 9 30
No subjects had isolated perforator incompetence or deep  perforator
incompetence.
Table II. Demographic data and coexistent medical illnesses
Control groups (n  13) Therapy groups (n  17) Both groups (n  30)
n % n % n %
Mean age (y) 70 71 70
Height (in) 69 69 69
(m) 1.75 1.75 1.75
Weight (lb) 239 223 230
kg 108 101 104
BMI (kg/m2) 35.3 32.9 33.9
Ankle-brachial index 1.16 1.16 1.16
Diabetes 4 31 6 35 10 33
Dyspnea 5 39 6 35 11 37
Arterial hypertension 10 77 7 41 17 57
Angina 3 23 1 6 4 13
Heart failure 2 15 1 6 3 10
Coronary artery disease 4 31 3 18 7 23
Arthritis 5 39 8 47 13 43
Other musculo skeletal (eg, back, knee) 5 39 9 53 14 47
Prior vein operation 1 8 3 18 4 13
Prior thrombosis 8 62 7 41 15 50
IVC filters 1 8 1 6 2 7
All patients were men.
All P values nonsignificant.
BMI, Body mass index; IVC, inferior vena cava.
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also exhibit pathologic changes consistent with atrophy,
necrosis, and inflammation in limbs with venous insuffi-
ciency.21 Although many patients with CVI are elderly,
physical therapy can still be effective, and supervision of the
exercise provides a superior response.20,22 The beneficial
effects of muscle stretch and strengthening are rapidly
induced, and are sustainable with minimal additional ther-
apeutic encounters.23,24
Significant venous dysfunction is present within 5 days
of acute, stabilized ankle fractures, but recovers by 18
weeks.25 Unlike reversible musculoskeletal injury, limbs
with severe CVI are subjected to prolonged venous hyper-
tension.3,5 Short-term (6 weeks) exercise with pedal er-
gometry significantly improved ankle joint motion and
symptoms of pain and limb swelling in an observational
study from Germany.26 Yang et al,27 who conducted a
single-arm pilot study evaluating calf strengthening in rela-
tionship to calf pump function, also used multiple baseline
studies to reduce variability in APG and Biodex measure-
ments. After a limited exercise program consisting predom-
Table IV. CEAP characterization
Clinical
Control group
(n  13)
Therapy group
(n  17)
Both groups
(n  30)
Pn % n % n %
Clinical class
4 7 54 11 64 18 60
5 3 23 3 18 6 20
6 3 23 3 18 6 20
Etiology
Primary 5 38 11 65 16 53
Secondary 8 61 6 35 14 47
Anatomy: see Table III
Pathophysiology
Reflux 9 69 13 77 22 73
Obstruction
Reflux/obstruction 4 31 4 23 8 27
Venous clinical scores (mean  SEM)
VCSS total (0-30) 9.77  1.29 9.35  84 .781
Clinical score (0-18) 5.23  .89 4.76  .81 .703
Disability score (0-3) 1.15  .27 1.24  .18 .799
Anatomic score
Reflux (0-10) 4.27  .62 5.09  .333 .261
Obstruction (0-10) 1.50  .60 .92  .53 .473
There was no congenital etiology or pure obstructive pathophysiology.
Percentages represent a proportion of each group in the category.
VCSS  Venous Clinical Severity Score.
Table V. Air plethysmography and VCSS values in each group at baseline and 6 months later
Parameter Normal values
Baseline
(mean  SEM)
6 Months
(mean  SEM)
Baseline to 6-month Change
(mean  SEM)
Control
group
Therapy
group P*
Control
group
Therapy
group P*
Control
group
Therapy
group
P treatment
effect‡
APG n  13 n  17 n  13 n  15† n  15 n  15†
EF (%) 60%;40% poor 33.1 2.6 41.7 3.3 .06 31.7 2.9 46.6 3.1 .002 1.4 2.1 3.48 2.7 .03
RVF (%) 5%-35% 36.2 4.4 38.0 3.7 .76 39.6 4.9 29.5 2.9 .08 3.4 2.9 8.75 4.6 .03
VFI (ml/min) 2.0§ 7.28 0.9 6.30 .07 .39 7.3 0.97 6.6 0.90 .65 .01 0.6 .58 0.5 .64
OF (%) 38%;28% poor 51.6 3.0 55.0 2.3 .36 45.7 2.9 60.1 2.7 .001 5.9 1.8 4.4 2.8 .001
VV (mL) 80-150 mL 141 12 120 7.5 .15 158.9 22 135.9 12 .35 17.8 12.8 15.2 6.8 .69
EV (mL) 44.5 3.6 48.9 4.2 .46 46.1 5.2 63.1 6.7 .06 1.6 3.2 12.4 4.7 .06
VCSS n 14 n 18 n 13 n 15 n 13 n 15
Total 9.8 1.29 9.4 0.8 .76 9.8 1.2 8.7 0.8 .388 .08 1.0 .3 0.9 .51
EF, Ejection fraction; RVF, residual volume fraction; VFI, venous filling index; OF, outflow fraction; VV, venous volume; EV, ejected volume; VCSS, Venous
Clinical Severity Scores.
*t-test of group differences at given point in time.
†Two subjects did not return for 6-month follow-up evaluation.
‡Probability of difference in residualized outcomes (stochastic estimate of change) between therapy and control groups based on F test from hierarchical
ANOVA (controlling for initial baseline values of same measure). All baseline values (covariates) affected APG outcomes, with P .004; r .539-.850 between
pretest and posttest air plethysmography values.
§VFI  9 mL/min associated with high incidence of ulcer.
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inantly of toe raises in a 6-week, home-based program, they
too found significant differences in both EF and RVF;
although strength and power demonstrated a trend toward
improvement, it did not achieve statistical significance.27,28
More recently Kan and Delis29 randomized 10 patients
with C6 disease to an 8-day program of supervised calf
muscle exercise, with age-matched control subjects. They
also demonstrated improvement in calf pump function;
however, they also reported an increase in endurance man-
ifested by doubling of the repetitions of the exercise.29
Although acute thromboses were excluded from our inves-
tigation, Partsch et al30 also reported improved outcomes
in pain, edema, and clinical scores in a randomized trial of
early ambulation (with compression and low molecular
weight heparin therapy) compared with bed rest (with
heparin therapy) in patients with acute proximal venous
thrombosis.
Thus our findings confirm the hypothesis that a struc-
tured program of calf muscle exercise can improve hemo-
dynamic performance. Both calf pump function (EF, RVF)
and strength (peak torque per unit body weight) were
improved after participation in the supervised exercise pro-
gram. These data do not assess whether this benefit could
be achieved in a shorter time or with exercise regimens that
differ in intensity from those used in the current study.
They do indicate that benefit can be sustained for at least 3
months after termination of supervised exercise. To deter-
mine the appropriate intensity of exercise, its supervision,
its duration, and the need for interval reinforcement would
require a larger, multicenter study. Since adjunctive therapy
would appear to be complementary for limbs with CVI,
further investigation into its role is warranted.
Since APG is completely noninvasive, frequent, re-
peated measurements are well-accepted by the subjects.
This is in contrast to the reluctance expressed by patients
asked to participate in studies that require repetitive venous
puncture.5,14 Consistent with previous reports, no changes
in reflux as measured with VFI were observed.27,29 While
superficial venous ablation has a dramatic effect on reflux,
calf pump function, and improved QOL, many of the
subjects in this protocol had prior deep venous thromboses
and would not have been ideal candidates for saphenous
vein surgery.1,2. Thus therapy may offer an additional ad-
junctive therapy for individuals who are not candidates for
traditional venous surgery. Since class II (30-40 mm Hg)
stockings were provided and monitored, with excellent
compliance in both groups, the treatment benefit accrued
from therapy cannot be attributed to compression hosiery
or variations in its use.
Although outflow fraction was determined to be differ-
ent between control and experimental groups, this finding
is unlikely to be of clinical significance. The mean values
were all in the normal physiologic range. It is not known
whether patients with severely restricted outflow fraction
would have responded to this therapeutic intervention.
Isokinetic dynamometers are designed to allow for
testing to be constrained to a variety of angular velocities,
from 2 to more than 300 degrees per second. The fast speed
(120 degrees per second) is considered a functional velocity
for fast walking. Activities of daily living require that high-
Table VI. Physical performance (Biodex) outcomes in each group at 6 months
Parameter
Baseline
(mean  SEM)
6 months
(mean  SEM)
Baseline to 6-month changes
(mean  SEM)
Control
group
n  13
Therapy
group
n  17 P*
Control
group
n  13
Therapy
group
n  16 P*
Control
group
n  16
Therapy
group*
n  16†
P treatment
effect‡
Slow speed (60 rpm)
Peak torque (ft-lb) 31.2  3.9 22.2  2.7 .06 28.1  2.8 30.5  3.2 .59 3.1  3.0 7.3  3.2 .14
Peak torque/body weight 12.9  1.2 10.7  1.7 .33 11.9  1.0 14.3  1.7 .27 1.0  1.1 3.1  1.4 .05
Maximum repetitions work
(ft-lb)
13.8  2.2 8.4  1.3 .04 11.6  1.7 11.0  1.4 .79 2.1  1.9 2.2  1.2 .38
Total work (ft-lb) 54.1  8.1 33.8  5.5 .04 51.8  7.4 48.1  6.3 .70 2.3  4.2 12.4  5.6 .21
Average power (W) 20.0  3.1 12.4  1.7 .05 19.1  2.3 19.8  2.5 .83 .9  2.5 6.7  2.5 .23
Maximum active ROM (°) 34.2  1.5 33.8  2.1 .88 35.5  2.3 34.1  2.3 .68 1.3  1.3 .1  1.1 .48
Fast speed (120 rpm)
Peak torque (ft-lb) 26.3  1.9 18.9  1.8 .01 25.2  2.2 25.7  2.2 .90 1.0  1.7 6.4  2.1 .096
Peak torque/body weight 11.0  0.5 9.1  1.2 .17 10.7  .82 12.0  1.2 .41 .3  0.6 2.8  0.9 .03
Maximum repetitions work
(ft-lb)
10.7  1.6 7.1  .96 .02 10.5  1.4 9.28  .92 .47 .2  0.9 2.2  0.8 .18
Total work (ft-lb) 117  13.2 81.4  11.9 .05 122.3  15 107.3  12 .43 4.7  6.5 27.7  11.7 .42
Average power (Ws) 19.1  3.3 13.7  2.1 .16 19.5  2.5 17.9  2.0 .62 .4  1.7 3.3  1.6 .51
Maximum active ROM (°) 31.7  1.7 29.8  1.8 .43 34  2.4 30.3  2.0 .25 2.3  1.4 .9  1.0 .48
rpm, Revolutions per minute; ROM, range of motion; °, degrees of rotation. Physical performance measures are described in the text.
*Based on t test comparing control with therapy groups at each point in time.
†One therapy case did not return for 6 month follow-up Biodex evaluation.
‡Probability of difference in residualized outcomes based on F test from hierarchical ANOVA controlling for baseline values. Baseline Biodex covariates affected
Biodex outcomes with P .007; r  .494 to .775 between pretest and posttest values.
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demand tasks, such as avoiding a sudden fall or walking, can
be accomplished quickly. The slower speed (60 degrees per
second) would be required for more strength-related activ-
ities, such as stair climbing. Participants were asked to exert
maximal effort as fast as possible throughout the available
ROM. Biodex-generated maximal ROM values were con-
sistent with those previously reported for active ROM.4
The absence of a change with intervention suggests that a
contracted tendon may not respond to the duration of
therapy used. Variability is common in measures of human
performance, including Biodex dynamometry.
An extension of benefits into generalized QOL and
improved functional mobility was not demonstrated, de-
spite the use of multiple survey instruments, including two
specifically targeted for venous insufficiency. The subjects
selected all had advanced CVI; although these question-
naires were intended to evaluate the widely varied complete
spectrum of CVI, they have been most frequently used for
evaluation of less severe forms of venous insufficiency.
The frequency of ineligibility was surprising. Common
reasons were refusal to consider the exercise option, pref-
erence for surgery, and clinical findings without anatomic
evidence of venous disease. In fact, many of the 20 mor-
bidly obese patients described in 2002 were identified
during screening for this protocol.18 Since most had no
anatomic evidence of CVI, we thought it best to exclude
these individuals, because their performance may not accu-
rately reflect experimental therapy for CVI. If, however,
obesity were itself a cause of CVI, exercise would serve the
dual roles of calf strengthening and encouraging increased
energy utilization. Unfortunately, these patients are often
too ill to consider more than minimal activity.
The primary limitation of the present study is the
sample size. A sample size of 60 patients was calculated to
achieve at least a 9.9% difference in RVF, with a priori
analysis, but we did not attain this sample size. A nonsig-
nificant trend toward greater medical comorbidity was
noted in the control group, and slightly greater musculo-
skeletal problems were observed in the experimental group.
Generalizability of results of any study is usually unclear
without a substantial sample size and replication at various
sites. A larger randomized study with multiple sites could
attain greater comparability of experimental and control
groups and provide a more precise picture of the benefits of
structured exercise on CVI. Therefore we recommend con-
sideration of a larger, multicenter study to confirm and
clarify the effects of physical therapy on CVI, the effects on
QOL, and the degree of benefit to patients.
Exercise improved calf pump hemodynamics, specifi-
cally, EF and RVF. Calf muscle strength improved at both
slow and fast speeds when normalized to body weight.
These data support further consideration of structured
exercise as additional treatment for management of severe
CVI.
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DISCUSSION
Dr Kevin G. Burnand (London, England). You obviously
had more people who were excluded from the study than actually
took part. What you didn’t tell us was the age of these patients. You
visited the ulcer clinic at St. Thomas’s, and I wondered how many
of our 80-year-old female patients would be appropriate for your
exercise program?
Dr Frank T. Padberg. Some of the patients I saw in your
clinic would indeed not have been any more eligible than some of
those we excluded from ours.
The average age was a uniform 70.
Some of the patients excluded were reported at this meeting
last year. The morbidly obese group was excluded because they had
no anatomic evidence of venous disease; although they exhibited
skin changes and ulceration, duplex scans and results of air pleth-
ysmography were normal.
Dr Thomas W. Wakefield (Ann Arbor, Mich). Frank, this
was a very nice study. I have one question.
When you did the APG studies, were the patients wearing
stockings or not wearing stockings? We have seen differences in
APG results whether or not the patients are wearing their stockings
at the time of the study.
Dr Padberg. We uniformly requested that they remove their
stockings for these studies; that way we could compare the baseline
values that were achieved before they received stockings with those
that we achieved with the therapeutic intervals.
Dr Paul Perkowski (Phoenix, Ariz). I have two questions.
Number one, do you have any information on the clinical
significance of this? What percentage of patients healed their ulcers
or had freedom from recurrence of ulcers?
And the second question is, what do you think is the patho-
physiology of this exercise program? Since we know the primary
pathology is valvular incompetence, how do you think this exercise
helps with that?
Dr Padberg. Let me take the second one first. There is
evidence of direct muscle damage in patients with CVI, which is
referenced in the text. Even though the muscle is damaged, we
presume that it can still be conditioned to improve strength and
that the calf muscle pump may compensate to some extent for
reflux. We reported several years ago a sensory deficit, which was
also associated with chronic venous insufficiency in these patients.
As regards the clinical significance, we didn’t ask that question
specifically. Our outcome variables were hemodynamic changes or
muscle strengthening. We assess healing of ulceration as a primary
outcome variable and did not expect to achieve healing as a result
of this treatment option. We were really only looking for whether
or not we could make a difference in terms of either hemodynamics
or exercise strengthening. There is obviously potential for further
study, and long-term follow-up will be required to determine the
value of therapy as an adjunctive mechanism to maintain limbs in the
healed state.
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